Business
Humacyte Receives Symvess® Purchase Commitment for Clinical Evaluation and Outreach Program in the Kingdom of Saudi Arabia
- Purchase commitment is for a minimum of $1.475 million of Symvess product -DURHAM, N.C., March 19, 2026 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a commercial-stage biotechnology platform company developing universally implantable, bioengineered human tissues at commercial scale, today announced that it has received a minimum purchase commitment of $1.475 million of the Symvess acellular tissue engineered vessel to facilitate a clinical evaluation and outreach program in hospitals wit
About this update from Humacyte, Inc.
[{"type":"image","alt":"Humacyte, Inc","displaySize":"","headline":null,"caption":"Humacyte, Inc","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":57,"url":"https://media.zenfs.com/en/globenewswire.com/6664e34870555953d37f7abc79cd102e"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/mm54aqS3.8GpFHiIkOCKDg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTgw/https://media.zenfs.com/en/globenewswire.com/6664e34870555953d37f7abc79cd102e","width":300,"height":57}},"lazy":false},{"type":"text","content":"- Purchase commitment is for a minimum of $1.475 million of Symvess product -","length":77,"tagName":"p"},{"type":"text","content":"DURHAM, N.C., March 19, 2026 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a commercial-stage biotechnology platform company developing universally implantable, bioengineered human tissues at commercial scale, today announced that it has received a minimum purchase commitment of $1.475 million of the Symvess acellular tissue engineered vessel to facilitate a clinical evaluation and outreach program in hospitals within the Kingdom of Saudi Arabia (KSA). The planned clinical evaluation program is to be conducted in parallel with ongoing negotiations with a KSA-based entity for establishment of a joint venture and license to commercialize Symvess within the country. Humacyte will provide personnel to train medical professionals in the use of Symvess as part of the program and has agreed to not engage in negotiation of commercialization rights within the KSA with any other party through July 2, 2026.","length":914,"tagName":"p"},{"type":"text","content":"“We are pleased to take another step forward in our planned global expansion of Symvess,” said Laura Niklason, M.D., Ph.D., Founder and Chief Executive Officer of Humacyte. “The clinical evaluation and outreach program is designed to build awareness and understanding of the Symvess technology among healthcare providers as we pursue regulatory approval and prepare for potential commercial launch in the KSA. We look forward to initiating the program and will provide updates as planned negotiations for the commercialization structure within the KSA are concluded.”","length":567,"tagName":"p"},{"type":"text","content":"For uses other than the FDA approval in the extremity vascular trauma indication, Symvess is an investigational product and has not been appr...